This is an outdated version published on 08-03-2026. Read the most recent version.

A complete study of Doxazosin characterization

Authors

  • Itamar Luís Gonçalves Laboratório de Síntese Orgânica Medicinal/LaSOM do Programa de Pós-Graduação em Ciências Farmacêuticas/PPGCF da Universidade Federal do Rio Grande do Sul
    • Mariana Maier Gaelzer Programa de Pós-Graduação em Ciências Biológicas: Bioquímica do Instituto de Ciências Básicas da Saúde da Universidade Federal do Rio Grande do Sul
      • Gabriel Oliveira de Azambuja Laboratório de Síntese Orgânica Medicinal/LaSOM do Programa de Pós-Graduação em Ciências Farmacêuticas/PPGCF da Universidade Federal do Rio Grande do Sul
        • Christianne Gazzana Salbego Programa de Pós-Graduação em Ciências Biológicas: Bioquímica do Instituto de Ciências Básicas da Saúde da Universidade Federal do Rio Grande do Sul
          • Vera Lucia Eifler-Lima Laboratório de Síntese Orgânica Medicinal/LaSOM do Programa de Pós-Graduação em Ciências Farmacêuticas/PPGCF da Universidade Federal do Rio Grande do Sul

            DOI:

            https://doi.org/10.22456/2527-2616.73960

            Keywords:

            doxazosin, NMR, FT-IR, signals assignment

            Abstract

            Doxazosin is an important drug used to treat hypertension and prostatic hyperplasia. An enantiomeric (R)/(S) doxazosin
            mesylate mixture was complete characterized by NMR and additionally FT-IR spectroscopy techniques. Different NMR
            experiments were performed, such as APT, HSQC, and HMBC in order to confirm the NMR signals assignments. All the
            hydrogens and most of carbons atoms were assigned. In this context, the results reported here, consists in important
            information for identification and quality control of doxazosin mesylate.

            Downloads

            Download data is not yet available.

            References

            Wykretowicz, A., Guzik, P., Wysocki, H. Doxazosin in the current treatment of hypertension. Expert opinion on pharmacotherapy. 2008;9(4):625-33. DOI: https://doi.org/10.1517/14656566.9.4.625

            Wilt, T.J., MacDonald, R. Doxazosin in the treatment of benign prostatic hypertrophy: an update. Clinical interventions in aging. 2006;1(4):389. DOI: https://doi.org/10.2147/ciia.2006.1.4.389

            Pfizer. Company History 2017 [cited 2017 20/07/2017]. Available from: http://www.pfizer.com/about/history/all.

            Gaelzer, M.M., Coelho, B.P., de Quadros, A.H., Hoppe, J.B., Terra, S.R., Guerra, M.C.B., et al. Phosphatidylinositol 3-Kinase/AKT pathway inhibition by doxazosin promotes glioblastoma cells death, upregulation of p53 and triggers low neurotoxicity. PloS one. 2016;11(4):e0154612. DOI: https://doi.org/10.1371/journal.pone.0154612

            Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., Sukhatme, V.P., Vikas, P. The repurposing drugs in oncology (ReDO) project. ecancermedicalscience. 2014;8. DOI: https://doi.org/10.3332/ecancer.2014.485

            González-Juanatey, J.R., Iglesias, M.J., Alcaide, C., Piñeiro, R., Lago, F. Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of α 1-adrenergic blockade. Circulation. 2003;107(1):127-31. DOI: https://doi.org/10.1161/01.CIR.0000043803.20822.D1

            Nikolic, K., Filipic, S., Smoliński, A., Kaliszan, R., Agbaba, D. Partial least square and hierarchical clustering in ADMET modeling: Prediction of blood– brain barrier permeation of α-adrenergic and imidazoline receptor ligands. Journal of Pharmacy & Pharmaceutical Sciences. 2013;16(4):622-47. DOI: https://doi.org/10.18433/J3JK5P

            Bakshi, M., Ojha, T., Singh, S. Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions. Journal of Pharmaceutical and Biomedical Analysis. 2004;34(1):19-26. DOI: https://doi.org/10.1016/j.japna.2003.08.009

            Yuan, X-R., Liu, Y-H., Li, R-Y., Chen, X-X. Experimental and theoretical NMR study of (s)- doxazosin. Acta Physico-Chimica Sinica. 2008;24(6):1058-62. DOI: https://doi.org/10.3866/PKU.WHXB20080625

            Loidreau, Y., Besson, T. Microwave-assisted thermal decomposition of formamide: a tool for coupling a pyrimidine ring with an aromatic partner. Tetrahedron. 2011;67(26):4852-7. DOI: https://doi.org/10.1016/j.tet.2011.05.010

            Rouf, A., Aga, M.A., Kumar, B., Taneja, S.C. A facile approach to chiral 1, 4-benzodioxane toward the syntheses of doxazosin, prosympal, piperoxan, and dibozane. Tetrahedron Letters. 2013;54(48):6420-2. DOI: https://doi.org/10.1016/j.tetlet.2013.09.040

            Tsyskovskaia, I., Kandil, M., Beaumier, Y. Synthesis of a New Doxazosin‐Related Compound. Synthetic communications. 2007;37(3):447-50. DOI: https://doi.org/10.1080/00397910601039135

            Zhang, L-Y., Wang, B-L., Zhan, Y-Z., Zhang, Y., Zhang, X., Li, Z-M. Synthesis and biological activities of some fluorine- and piperazine-containing 1,2,4- triazole thione derivatives. Chinese Chemical Letters. 2016;27(1):163-7. DOI: https://doi.org/10.1016/j.cclet.2015.09.015

            Koester, L.S., Guterres, S.S., Le Roch, M., EiflerLima, V.L., Zuanazzi, J.A., Bassani, V.L. Ofloxacin/βCyclodextrin Complexation. Drug Development and Industrial Pharmacy. 2001;27(6):533-40. DOI: https://doi.org/10.1081/DDC-100105178

            Commission BP. British Pharmacopoeia. London2013.

            Pharmacopeia U. United States Pharmacopeia. The Standard USA: US Pharmacopeia 1995. 2002.

            Downloads

            Published

            28-08-2017 — Updated on 08-03-2026

            Versions

            How to Cite

            Gonçalves, I. L., Maier Gaelzer, M., Oliveira de Azambuja, G., Gazzana Salbego, C., & Eifler-Lima, V. L. (2026). A complete study of Doxazosin characterization. Drug Analytical Research, 1(1), 56–60. https://doi.org/10.22456/2527-2616.73960 (Original work published August 28, 2017)

            Issue

            Vol. 1 No. 1 (2017)

            Section

            ORIGINAL ARTICLES

            License

            Copyright (c) 2017 Drug Analytical Research

            Creative Commons License

            This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

            The Copyright holder of manuscripts published is Drug Analytical Research. Authors who publish with this journal are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.


            Licensing:

            Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

            Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author.

            Crossref
            Scopus
            Google Scholar
            Europe PMC

            Similar Articles

            You may also start an advanced similarity search for this article.